Orris

Anemia treatment in MHD patients give poster form

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Generating Image
Anemia Treatment in MHD Patients Poster
Here is the clinical poster on Anemia Treatment in Maintenance Hemodialysis (MHD) Patients, covering all key domains:

Poster Summary

Pathophysiology
  • Primary cause: reduced EPO production by failed kidneys + iron deficiency from dialysis-related blood losses + hepcidin-mediated iron sequestration due to chronic inflammation
Diagnostic Targets (KDIGO 2012)
ParameterTarget
Hemoglobin10–11.5 g/dL
Serum Ferritin>200 ng/mL
TSAT>20%
%Hypochromic RBCs<10%
Three Treatment Pillars
  1. ESAs — Epoetin alfa/beta (3×/week IV/SC), Darbepoetin alfa (weekly/Q2W), CERA (monthly). Initiate when Hb <10 g/dL after iron replete. Avoid Hb >13 g/dL (↑ CVD/stroke risk).
  2. IV Iron — Preferred over oral in dialysis patients. Agents: iron sucrose, ferric carboxymaltose, ferumoxytol, ferric gluconate. IV iron reduces ESA dose requirements significantly.
  3. Adjuncts/Emerging — HIF-PHI (Roxadustat, Daprodustat) — oral agents stimulating endogenous EPO; Blood transfusion as last resort (risk: HLA sensitization, iron overload).
ESA Hyporesponsiveness — Defined as Hb rise <1 g/dL despite high ESA doses. Most common cause: iron deficiency. Others: infection, hyperparathyroidism, pure red cell aplasia (anti-EPO antibodies), B12/folate deficiency.
Monitoring — Monthly CBC/Hb; Every 3 months: ferritin, TSAT; Every 6 months: PTH, B12, folate.
Sources: Brenner & Rector's The Kidney | KDIGO Anemia Guidelines 2012 | Comprehensive Clinical Nephrology 7th Ed.

Generate a comparison table of ESA agents (epoetin vs darbepoetin vs CERA)

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Generating Image
ESA Agents Comparison Table in MHD Patients
Here is the full comparison table. Key takeaways from the textbooks:

ESA Agents at a Glance

ParameterEpoetin α/βDarbepoetin αCERA
Generation1st2nd3rd
Half-life (IV)4–11 h~25 h~130 h
Half-life (SC)~24 h~48 h~140 h
Dosing2–3×/weekWeekly or Q2WOnce monthly
SC vs IV doseSC ~30% more efficientSame dose both routesSame dose both routes
Conversion ratioReference200 IU epoetin = 1 mcg120 IU epoetin = 1 mcg
PRCA riskHigher (esp. SC epoetin alfa)LowLow
CostLowestModerateHighest
BiosimilarsMany availableYesLimited
Structural basis for prolonged half-life:
  • Darbepoetin: 2 extra N-linked glycosylation chains → reduced clearance
  • CERA: PEGylation of epoetin beta → dramatically slows clearance
Shared safety caveat: All ESAs carry risk of hypertension, thrombosis, and stroke when Hb exceeds 13 g/dL (demonstrated in CREATE, CHOIR, and TREAT trials). Target Hb remains 10–11.5 g/dL for all three agents per KDIGO 2012.
Sources: Comprehensive Clinical Nephrology 7th Ed. | Brenner & Rector's The Kidney
This is a shared conversation. Sign in to Orris to start your own chat.